For example, combination of ipilimumab and nivolumab (an anti‐PD‐1 antibody) is approved in the treatment of advanced renal cell carcinoma and mismatch repair deficient (dMMR) CRC [117, 118, 142]. Here, PDCD1 is linked to colorectal carcinoma.